This article summarized the latest R&D progress of Salicylamide, the Mechanism of Action for Salicylamide, and the drug target R&D trends for Salicylamide.
Catechol O-methyltransferase (COMT) is an enzyme responsible for the O-methylation of endogenous neurotransmitters, xenobiotics, and hormones with catechol structures.
This article summarized the latest R&D progress of Vilobelimab, the Mechanism of Action for Vilobelimab, and the drug target R&D trends for Vilobelimab.
This article summarized the latest R&D progress of Thioguanine, the Mechanism of Action for Thioguanine, and the drug target R&D trends for Thioguanine.
Edgewise Therapeutics initiates its first-in-human Phase 1 trial for EDG-7500, the primary clinical contender for Hypertrophic Cardiomyopathy and other severe Cardiac Diastolic Dysfunction conditions.
Chemokines, also known as chemotactic cytokines, are a group of factors that, in conjunction with their cell surface receptors, induce the directed migration of leukocytes.
This article summarized the latest R&D progress of Quinidine Gluconate, the Mechanism of Action for Quinidine Gluconate, and the drug target R&D trends for Quinidine Gluconate.
NextCure Inc. and Yale Cancer Center announced Phase 2 trial results today, indicating a combined NC318 and Pembrolizumab regimen is beneficial for advanced non-responsive PD-1 non-small cell lung cancer patients.